Psychiatry & Neurology, Neuromuscular Medicine · Seattle, WA
NPI
1518986199
Since 2006
Specialty
Psychiatry & Neurology, Neuromuscular Medicine
Code 2084N0008X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
550 17th Ave Ste 400
Seattle, WA, 98122
Phone (206) 320-2840
Groups this clinician bills Medicare through
Medicare paid, 2024
$105K
9,616 services
Medicare patients, 2024
161
Average age 71
Drug cost, 2024
$2.8M
880 prescriptions
Company payments, 2025
$5,475
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael A Elliott was code J0585 (injection, onabotulinumtoxina, 1 unit), 8,200 times for 19 patients. In total Michael A Elliott billed 9,616 services in 24 codes, and Medicare paid $105K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-09-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 8,200 | 19 | $4.55 | $37K |
| 99215 Office E&M - Established | Office | 147 | 67 | $145.56 | $21K |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 95 | 42 | $26.21 | $2,490 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 95 | 55 | $13.70 | $1,301 |
| 95886 Electrical Nerve Conductivity | Office | 79 | 56 | $85.96 | $6,791 |
| 64612 Musculoskeletal | Office | 38 | 11 | $158.56 | $6,025 |
| 99214 Office E&M - Established | Office | 37 | 27 | $101.65 | $3,761 |
| 95910 Electrical Nerve Conductivity | Office | 30 | 30 | $151.98 | $4,559 |
| 95911 Electrical Nerve Conductivity | Office | 22 | 22 | $181.73 | $3,998 |
| 99205 Office E&M - New | Office | 11 | 11 | $182.47 | $2,007 |
By year: 2022 $93K for 7,379 services; 2023 $101K for 8,532 services; 2024 $105K for 9,616 services.
Medicare prescription drug claims, 2024
In 2024, the drug Michael A Elliott prescribed most often to Medicare patients was Radicava Ors (Edaravone), with 160 prescriptions and refills. In total Michael A Elliott wrote 880 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Radicava Ors Edaravone | 160 | 160 | 18 | $2.2M |
| Riluzole Generic | 141 | 172 | 28 | $23K |
| Baclofen Generic | 91 | 134 | 18 | $2,368 |
| Nuedexta Dextromethorphan Hbr/Quinidine | 62 | 64 | Under 11 | $99K |
| Gabapentin Generic | 35 | 52 | Under 11 | $755 |
| Glycopyrrolate Generic | 34 | 36 | Under 11 | $818 |
| Relyvrio Sod Phenylbutyrat/Taurursodiol | 30 | 32 | 14 | $408K |
| Mycophenolate Mofetil Generic | 27 | 63 | Under 11 | $3,889 |
| Mexiletine Hcl Generic | 20 | 28 | Under 11 | $1,313 |
| Solu-Medrol Methylprednisolone Sod Succ/Pf | 18 | 18 | Under 11 | $119 |
| Tramadol Hcl Generic | 17 | 17 | Under 11 | $152 |
| Citalopram Hbr Citalopram Hydrobromide | 16 | 36 | Under 11 | $186 |
| Trazodone Hcl Generic | 14 | 27 | Under 11 | $148 |
| Pyridostigmine Bromide Generic | 14 | 31 | Under 11 | $1,842 |
| Aimovig Autoinjector Erenumab-Aooe | 12 | 12 | Under 11 | $8,830 |
Brand drugs: - claims; generic drugs: 565 claims; opioid claims: 19.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael A Elliott $5,475 ($5,475 in general payments such as food, travel and fees) from 1 company. The largest payer was Tanabe Pharma America, Inc. with $5,475.
| Company | Payments | Amount |
|---|---|---|
| Tanabe Pharma America, Inc. | 3 | $5,475 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.